Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Cardiovascular Injury

    Current Location

    Search
    Cardiovascular Injury
    Show Map
    Map View
    Your Location
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      13 Cardiovascular Injury Trials Near You

      Power is an online platform that helps thousands of Cardiovascular Injury patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Anti-androgen Treatment for Prostate Cancer

      Columbus, Ohio
      Learning about the impact of anti-androgen treatment has on cardiac function in patients with prostate cancer may help plan treatment and help patients live more comfortably. This pilot clinical trial will utilize cardiac magnetic resonance imaging (MRI) before a patient starts hormone therapy and after 4 to 7 months of hormone therapy. The objective is to measure the impact of hormone therapy (anti-androgen treatment) on cardiac function in patients with prostate cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Active Malignancy, Cardiovascular Disease, Others
      Must Be Taking:Anti-androgens

      23 Participants Needed

      Rivaroxaban + ASA for Hip Fracture

      Hamilton, Ontario
      A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular events. Among patients who have undergone hip fracture surgery and have evidence of myocardial injury, to explore the feasibility of a randomized controlled trial (RCT) comparing rivaroxaban 2.5 mg twice daily + low-dose ASA (75-100 mg) for 90 days, with standard VTE thromboprophylaxis for 30 days, for prevention of major cardiovascular events. The HIPSTER-Pilot is a multicenter, international, open-label, pilot RCT with blinded outcome adjudication. A total of 100 participants aged ≥45 years who received hip fracture surgery and experienced a myocardial injury will be randomized to receive either rivaroxaban 2.5 mg twice daily plus ASA 75-100 mg daily for 90 days or standard VTE prophylaxis with an anticoagulant for 30 days. The primary feasibility outcome will be the recruitment rate. Other feasibility measures include completeness of follow-up and adherence to the treatment. Exploratory clinical outcomes will be assessed. This pilot trial will provide information on the feasibility of conducting a larger RCT to evaluate the efficacy and safety of the COMPASS regimen for preventing arterial and venous thrombotic events after hip fracture surgery in patients who have had myocardial injury. The results of this feasibility study will inform the design of the full-scale trial.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3
      Age:45+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Hepatic Disease, Others
      Must Not Be Taking:P-gp Inhibitors, CYP3A4 Inducers

      100 Participants Needed

      Spinal Stimulation for Spinal Cord Injury

      West Orange, New Jersey
      The goal of this clinical trial is to evaluate the effect of transcutaneous spinal cord stimulation on blood pressure in individuals with an acute spinal cord injury (within 30 days of injury). Blood pressure instability, specifically orthostatic hypotension (a drop in blood pressure when moving lying flat on your back to an upright position), appears early after the injury and often significantly interferes with participation in the critical rehabilitation time period. The main questions it aims to answer are: 1. Can optimal spinal stimulation increase blood pressure and resolve orthostatic symptoms (such as dizziness and nausea) when individuals undergo an orthostatic provocation (a sit-up test)? Optimal stimulation and sham stimulation (which is similar to a placebo treatment) will be compared. 2. What are the various spinal sites and stimulation parameters that can be used to increase and stabilize blood pressure to the normal range of 110-120 mmHg? Participants will undergo orthostatic tests (lying on a bed that starts out flat and then moved into an upright seated position by raising the head of bed by 90° and dropping the base of the bed by 90° from the knee) with optimal and sham stimulation, and their blood pressure measurements will be evaluated and compared.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Current Illness, Ventilator-dependent, Cancer, Others

      12 Participants Needed

      MitoQ for Cardiovascular Impairment from Early Life Stress

      Iowa City, Iowa
      Adverse childhood experiences (ACEs) represent highly stressful events in the first 18 years of life that include abuse, neglect, and household and community-level dysfunction. Greater exposure to ACEs are associated with greater increases in the risk of cardiovascular diseases and death. Our laboratory has previously observed that vascular function is disrupted in young adults with prior ACE exposure, even though these individuals appear to be healthy clinically (i.e., no classic clinical cardiovascular disease risk factors). There is a need to identify and understand the biological mechanisms underlying these vascular impairments to inform effective interventions to reduce cardiovascular risks the millions of individuals affected by ACEs. The body's response to stress is coordinated across various systems, all of which depend on energy supplied by mitochondria (often referred to as the "powerhouse of cells"). Based on new evidence across multiple physiological systems from our team, our overarching hypothesis is that disruption of mitochondrial function contributes to cardiovascular impairments among young adults with ACEs. Here we propose the initial pilot work necessary to begin to understand these associations, which will directly inform identification of individuals who may be most vulnerable to stress-related cardiovascular risk and the development of interventions to promote cardiovascular-stress resilience. Our aims are to: 1. Determine whether mitochondrial oxidative stress contributes to impaired vascular function among young adults who experienced early life adversity. 2. Determine whether reducing mitochondrial oxidative stress improves the cellular stress and integrated cardiovascular response to laboratory-based psychosocial stress among young adults who experienced early life adversity.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 29

      Key Eligibility Criteria

      Disqualifiers:Hypertension, Obesity, Alcohol, Drugs, Others
      Must Not Be Taking:Cardiovascular Drugs, SSRIs

      300 Participants Needed

      Spinal Stimulation for Cardiovascular Function After Spinal Cord Injury

      West Orange, New Jersey
      The study aims to explore how cardiovascular function changes in the first year after a spinal cord injury, and to see how different treatments, like spinal stimulation through the skin (transcutaneous spinal stimulation), affect blood pressure. The main questions are: How does stimulation affect blood pressure over the year? What is the level of cardiovascular activation throughout the year? The study will start during the inpatient stay at the Kessler Institute for Rehabilitation and continue after discharge as an outpatient, totaling about 20-29 sessions over the year.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Ventilator, Cardiac Devices, Heart Disease, Seizures, Others

      5 Participants Needed

      Testosterone Nasal Gel for Spinal Cord Injury

      The Bronx, New York
      Spinal cord injury (SCI) disrupts the nerves controlling movement, along with those that regulate functions like heart rate and blood pressure (known as the autonomic nervous system, or ANS). Testosterone (T) plays a significant role in brain health and ANS reflex function in non-neurologically impaired men. However, little is known about the relationships between T, nerve function, and ANS dysfunction after SCI. Interestingly, up to 60% of men with SCI exhibit persistently low T concentrations, which may worsen nerve and ANS dysfunction. In uninjured eugonadal people (normal physiologic range of serum T concentrations), a single pharmacologic dose of intranasal T has been shown to quickly improve nerve function, but no study has evaluated if T administration alters nerve and ANS function in men with SCI. Herein, the investigators will conduct the first study to test how a single dose of intranasal T impacts motor and ANS function in this population.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Seizures, Ventilator Dependence, Others
      Must Not Be Taking:Amphetamines, Neuroleptics, Others

      15 Participants Needed

      BRILLIANT Platform for Brain Injury

      Montreal, Quebec
      Background: Cardiovascular and neurological conditions are major causes of disability worldwide. Early, intensive rehabilitation is essential but often challenging to access in current healthcare systems. In Canada, the direct and indirect costs of acquired brain injury (ABI) are substantial, emphasizing the need for improved rehabilitation services. In collaboration with four health regions and the Canadian Foundation of Innovation (CFI) funded BRILLIANT research group, investigators are implementing a digital health platform (the BRILLIANT platform), which includes five modules to address current gaps and support a person-centered integrated care continuum for cardiovascular and neurological conditions. In this stepped wedge randomized trial, investigators plan to implement and evaluate the use of the BRILLIANT Platform for improving transitions of care in the rehabilitation of ABI individuals in Quebec. Methods: A stepped wedge cluster randomized trial will be conducted across four healthcare regions with eight programs. Eligible participants included new cardiovascular and neurological patients, caregivers, clinicians, coordinators, and managers. The BRILLIANT platform intervention, implemented in 2 phases, will provide standardized assessments, communication tools, shared intervention plans, self-management support, and quality improvement dashboards. Outcomes will include rehabilitation intensity measured in minutes, time from admission to rehabilitation, health-related quality of life, care experience, and costs. Data analysis will use mixed-effects models for quantitative data and content analysis for qualitative data. Discussion: This study will provide valuable evidence on the effectiveness and feasibility of the BRILLIANT platform in improving rehabilitation care for patients with cardiovascular and neurological conditions in Quebec. Investigators anticipate that by addressing the challenges and pursuing future directions, the implementation of this digital platform can contribute to improving patient outcomes and healthcare delivery.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      962 Participants Needed

      Management for Heart Attack After Surgery

      Montreal, Quebec
      Cardiac complications, particularly myocardial injury after noncardiac surgery (MINS), significantly contribute to 30-day mortality, affecting about 1 in 10 patients after noncardiac surgery. Despite its prevalence and serious implications, there is no consensus on managing myocardial injury after noncardiac surgery in clinical practice. Interventions commonly used for cardiovascular prevention in patients who had a heart attack outside of a surgery context could also be beneficial in patient with MINS. This pilot study trial aims to gather feasibility data, such as recruitment rates and intervention adherence that will guide on the design and inform on sample size of a future study with large pragmatic randomized controlled trial on the impact of systematic referral for secondary cardiovascular prevention on outcomes in patients who had a MINS.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Cirrhosis, Peptic Ulcer, Thrombocytopenia, Others
      Must Not Be Taking:Antiplatelets, Statins, ACEI/ARBs

      100 Participants Needed

      Walking Exercise Program for Stroke Survivors

      Kansas City, Kansas
      The goal of this clinical trial is to test a gait (walking) training program in non-ambulatory (unable to walk) chronic stroke survivors. The main question it aims to answer is: • Will gait training improve the cardiovascular system in non-ambulatory chronic stroke survivors better than a sitting leg cycling exercise? Participants will walk on a treadmill with a partial body-weight support system and the gait training device. Researchers will compare with a leg-cycling exercise to see if there are significant differences in resting heart rate, systolic blood pressure (SBP), and A1c levels in the blood.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Depression, Musculoskeletal Disorders, Others

      72 Participants Needed

      Pantoprazole for Acute Kidney Injury Prevention After Cardiac Surgery

      Houston, Texas
      The central hypothesis of this research study is that perioperative administration of the proton pump inhibitor (PPI) pantoprazole could reduce the development of acute kidney injury (AKI) following cardiac surgery by activation molecular pathways for kidney protection. The investigators propose a single-center, randomized, controlled, single-blinded trial to determine whether perioperative intravenous administration of pantoprazole will reduce the incidence of AKI, some molecules that can be detected the urine, and major adverse kidney events (MAKE) at day 30 postoperatively, compared to famotidine after cardiac surgery. The specific aims of the study will be achieved by randomizing a group of 400 patients to receive pantoprazole (study) or famotidine (control) for 3 days perioperatively. Our study population will include any adult patients (aged over 18 years) scheduled for cardiac surgery requiring a cardiopulmonary bypass machine.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Low EGFR, Dialysis, Pregnancy, Others

      400 Participants Needed

      Spinal Cord Stimulation + Arm Bike for Spinal Cord Injury

      Seattle, Washington
      Spinal cord injury (SCI) can make it hard for the body to self-regulate some of its automatic functions like blood pressure, breathing, and heart rate. This can also make it hard for those living with SCI to exercise or complete their usual daily activities. The goal of this randomized trial is to test combinatory therapy of moderate arm-crank exercise paired with non-invasive transcutaneous spinal cord stimulation (tSCS) for cardiovascular recovery in adults aged 21-65 following chronic motor-complete spinal cord injury (SCI) at or above the thoracic sixth spinal segment (≥T6). The main questions the study aims to answer are: * Conduct tSCS mapping to determine the most effective location and stimulation intensity for BP control in individuals with motor-complete SCI ≥ T6. * Evaluate the effects 8 weeks of targeted tSCS paired with arm-crank exercise compared to sham stimulation with exercise on improving cardiovascular function in individuals with motor-complete SCI ≥T6. * Evaluate the dosage-response of 8 weeks vs. 16 weeks of targeted tSCS paired with arm-crank exercise on cardiovascular function in individuals with motor-complete SCI ≥T6. * Explore the mechanisms involved in cardiovascular recovery with long-term tSCS paired with arm-crank exercise. Participants will: * Receive either transcutaneous spinal cord stimulation or "sham" spinal cord stimulation while exercising on an arm-crank bicycle in the first 8 weeks. * Come in for approximately 60 visits over a 6-month period. This includes 2, 8-week periods where the investigators will ask participants to come in 3x per week for spinal cord stimulation and exercise. * During assessment visits the researchers will perform a variety of exams including a neurologic, cardiovascular, pulmonary, physical, and autonomic exam, and will ask questions about quality of life and functioning. Researchers will compare those who receive tSCS and do moderate arm-crank exercise to those who receive a sham stimulation and do moderate arm-crank exercise to see if tSCS is effective at improving cardiovascular and autonomic functioning in those with SCI.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:21 - 65

      Key Eligibility Criteria

      Disqualifiers:Autoimmune, Neurologic, Neuropathy, Rheumatic, Others
      Must Not Be Taking:Antidepressants, Baclofen

      16 Participants Needed

      Spinal Cord Stimulation for Spinal Cord Injury

      Vancouver, British Columbia
      The aim of this study is to examine the mechanisms of transcutaneous spinal cord stimulation (tSCS) for improving cardiovascular and pulmonary function in individuals with chronic motor-complete spinal cord injury (SCI) by measuring vascular related endothelial biomarkers, plasma catecholamines, and respiratory parameters.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:19 - 65

      Key Eligibility Criteria

      Disqualifiers:Ventilator, Depression, Cardiovascular, Others
      Must Not Be Taking:Intrathecal Baclofen

      22 Participants Needed

      Telenutrition for Obesity in Spinal Cord Injury

      San Jose, California
      This study will provide nutrition counseling via FaceTime on an iPad to persons with traumatic spinal cord injury (SCI) who are overweight or obese and are at least one-year post-injury. Nutrition counseling may help participants to develop eating behaviors that match the participants' needs and help improve heart health. The purpose of this project is to decrease the risk of complications like obesity, high cholesterol, or diabetes, and explore associations between bowel and bladder function and nutrition. This study will require 3 in person visits that are about 3 months apart. The total length of the study is about 6 months and includes 3 months of telenutrition counseling.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:20+

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Hypertension, Diabetes, Pregnancy, Others
      Must Not Be Taking:Anti-diabetics

      96 Participants Needed

      Why Other Patients Applied

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Cardiovascular Injury Trial

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Clinical Trials near Arizona

      205 Clinical Trials near Hawthorne, CA

      Top Clinical Trials near Cincinnati, OH

      Top Clinical Trials near Anderson, SC

      Top Clinical Trials near Joliet, IL

      219 Clinical Trials near Glen Burnie, MD

      227 Clinical Trials near New York

      Top Eczema Clinical Trials near Tulsa, OK

      Top Myeloma Clinical Trials

      Top Clinical Trials near Bath, ME

      Top Sepsis Clinical Trials

      Top Prostate Cancer Clinical Trials near Kansas City, MO

      By Trial

      Communication Methods for Blood Donation Retention

      Fulvestrant + Ipatasertib for Breast Cancer

      Dapagliflozin for Heart Attack Recovery

      Spinal Cord Stimulation for Phantom Limb Pain

      Dronabinol for HIV/AIDS

      Telemedicine-Geriatric Care for Cancer

      Rimegepant + Zavegepant for Migraine

      Single Port Robotic Surgery for Colorectal Cancer

      NovoSorb BTM for Severe Burns

      LY3537031 for Obesity

      ChatBot Support for Cancer

      Nivolumab for Recurrent Prostate Cancer

      Frequently Asked Questions

      How much do Cardiovascular Injury clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Cardiovascular Injury clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Cardiovascular Injury trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Cardiovascular Injury is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Cardiovascular Injury medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Cardiovascular Injury clinical trials?

      Most recently, we added Rivaroxaban + ASA for Hip Fracture, MitoQ for Cardiovascular Impairment from Early Life Stress and BRILLIANT Platform for Brain Injury to the Power online platform.